141 related articles for article (PubMed ID: 22584361)
21. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
Fuertes Zamorano N; De Miguel Novoa MP; Molino González A; Díaz Pérez JÁ; Rojas-Marcos PM; Montañez Zorrilla MC
Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151
[TBL] [Abstract][Full Text] [Related]
22. [A case of pneumatosis intestinalis associated with sunitinib treatment for renal cell carcinoma].
Choi YA; Sim EH; Lee KE; Ko SY; Seo MJ; Yang YJ; Park JC; Park SY
Korean J Gastroenterol; 2013 Jun; 61(6):347-50. PubMed ID: 23877217
[TBL] [Abstract][Full Text] [Related]
23. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
Sella A; Hercbergs AH; Hanovich E; Kovel S
Chemotherapy; 2012; 58(3):200-5. PubMed ID: 22759787
[TBL] [Abstract][Full Text] [Related]
24. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC
Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib-induced thyrotoxicosis - a not so rare entity.
Jazvić M; Prpić M; Jukić T; Murgić J; Jakšić B; Kust D; Prgomet A; Bolanča A; Kusić Z
Anticancer Res; 2015 Jan; 35(1):481-5. PubMed ID: 25550591
[TBL] [Abstract][Full Text] [Related]
26. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Wong MK; Jarkowski A
Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
[TBL] [Abstract][Full Text] [Related]
27. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report.
Faris JE; Moore AF; Daniels GH
Thyroid; 2007 Nov; 17(11):1147-9. PubMed ID: 17714037
[TBL] [Abstract][Full Text] [Related]
28. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.
Michels J; Lassau N; Gross-Goupil M; Massard C; Mejean A; Escudier B
Invest New Drugs; 2010 Oct; 28(5):690-3. PubMed ID: 19547920
[TBL] [Abstract][Full Text] [Related]
30. Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome.
Talebi TN; Stefanovic A; Merchan J; Lian E; Silva O
Am J Ther; 2012 Jul; 19(4):e143-5. PubMed ID: 21403468
[TBL] [Abstract][Full Text] [Related]
31. Sunitinib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511
[TBL] [Abstract][Full Text] [Related]
32. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
33. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
[TBL] [Abstract][Full Text] [Related]
34. Sunitinib does not block thyroid peroxidase in patients.
Liwanpo L; Ro C; Haq S; Hershman JM
Thyroid; 2014 Aug; 24(8):1325-6. PubMed ID: 24521256
[No Abstract] [Full Text] [Related]
35. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
[No Abstract] [Full Text] [Related]
36. [Sunitinib and hypothyroidism].
Cohen R; Bihan H; Uzzan B; des Guetz G; Krivitzky A
Ann Endocrinol (Paris); 2007 Oct; 68(5):332-6. PubMed ID: 17707761
[TBL] [Abstract][Full Text] [Related]
37. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
38. The use of sunitinib in renal cell carcinoma: where are we now?
Czarnecka AM; Szczylik C; Rini B
Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
[TBL] [Abstract][Full Text] [Related]
39. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
Desai J; Yassa L; Marqusee E; George S; Frates MC; Chen MH; Morgan JA; Dychter SS; Larsen PR; Demetri GD; Alexander EK
Ann Intern Med; 2006 Nov; 145(9):660-4. PubMed ID: 17088579
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib-induced severe hypoglycemia in a diabetic patient.
Demirci A; Bal O; Durnali A; Ekinci AŞ; Eşbah O; Alkiş N; Oksüzoğlu B
J Oncol Pharm Pract; 2014 Dec; 20(6):469-72. PubMed ID: 24158980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]